Culturally adapted pharmacotherapy and the integrative formulation

Child and Adolescent Psychiatric Clinics of North America

Volumn 19, Issue 4, 2010, Pages 791-814

  Malik, Mansoor ^a   Lake, James ^b,c   Lawson, William B ^a   Joshi, Shashank V ^d  

^a HOWARD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

Complementary and alternative medicine; Culture; Cytochrome P450 enzyme system; Ethnopharmacology; Ethnopsychopharmacology; Integrative formulation; Integrative medicine; Pharmacotherapy

Indexed keywords

ALPHA TOCOPHEROL; ATOMOXETINE; CHLORPROMAZINE; CITALOPRAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; ESSENTIAL FATTY ACID; FERROUS SULFATE; GINSENG EXTRACT; HALOPERIDOL; HERBACEOUS AGENT; ICOSAPENTAENOIC ACID; LITHIUM; METHYLPHENIDATE; NATURAL PRODUCT; OLANZAPINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; PYCNOGENOL; SEROTONIN UPTAKE INHIBITOR; UNSATURATED FATTY ACID; ZINC;

ADJUVANT THERAPY; ATTENTION DEFICIT DISORDER; BEHAVIOR CONTROL; BLOOD PRESSURE; CHILD; CHILD PSYCHIATRY; CLINICAL TRIAL; CULTURAL VALUE; DEPRESSION; DIET RESTRICTION; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DYSKINESIA; ELECTROENCEPHALOGRAPHY; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; ETHNOPHARMACOLOGY; EXTRAPYRAMIDAL SYMPTOM; FAMILY THERAPY; HUMAN; INTEGRATIVE MEDICINE; LOW DRUG DOSE; MOTOR DYSFUNCTION; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; PSYCHOSOCIAL CARE; REVIEW; SIDE EFFECT; SOCIAL ADAPTATION; SOCIAL CLASS; SOCIAL PSYCHOLOGY; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; BIOFEEDBACK, PSYCHOLOGY; CHILD; CHILD PSYCHIATRY; COMPLEMENTARY THERAPIES; CULTURAL DIVERSITY; ETHNIC GROUPS; HUMANS; INTEGRATIVE MEDICINE; MENTAL DISORDERS; PATIENT CARE PLANNING; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME; UNITED STATES;

EID: 78149277731     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2010.08.003     Document Type: Review

References (116)

1. Lin K., Anderson D., Poland R. Ethnicity and psychopharmacology: bridging the gap. Psychiatr Clin North Am 1995, 18(3):635-647.
2. Chaudhry I.B., Neelam K., Duddu V., et al. Ethnicity and psychopharmacology. J Psychopharmacol 2008, 22:673.
3. US Census Figures Available at:, Accessed March 6, 2006. http://www.census.gov/.
4. US Department of Health and Human Services Mental health: culture, race, and ethnicity - a supplement to mental health: a report of the Surgeon General 2001, US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Rockville (MD).
5. Choi H. Understanding adolescent depression in ethnocultural context. ANS Adv Nurs Sci 2002, 25(2):71-85.
6. Dell M.L., Vaughan B.S., Kratochvil C.J. Ethics and the prescription pad. Child Adolesc Psychiatr Clin N Am 2008, 17:93-111.
7. Mintz D. Meaning and medication in the care of treatment-resistant patients. Am J Psychother 2002, 56(3):322-338.
8. Committee on Cultural Psychiatry of the Group for the Advancement of Psychiatry (GAP) Cultural assessment in clinical psychiatry 2002, American Psychiatric Press, Washington, DC, p. 6-7.
9. Pruett K, Joshi SV, Martin A. Thinking about prescribing: the psychology of psychopharmacology. In: Martin A, Scahill L, Kratochvil CJ, editors. Pediatric psychopharmacology, principles and practice. 2nd edition. New York: Oxford University Press; in press.
10. Gaw A.C. Cross-cultural psychopharmacology. Cross-cultural psychiatry 2001, American Psychiatric Press, Washington, DC. A.C. Gaw (Ed.).
11. Gaw A.C. Cultural context of nonadherence to psychotropic medications in psychiatry patients. Cross-cultural psychiatry 2001, 141-164. American Psychiatric Press, Washington, DC. A.C. Gaw (Ed.).
12. Munoz R., Primm A., Ananth J., et al. Disparities. Life in color: culture in American psychiatry 2007, 165-181. Hilton Publishing Company, Chicago.
13. Munoz R., Primm A., Ananth J., et al. Remedies in color. Life in color: culture in American psychiatry 2007, 105-125. Hilton Publishing Company, Chicago.
14. Smith M.W. Ethnopsychopharmacology. Clinical manual of cultural psychiatry 2006, 207-235. American Psychiatric Publishing, Washington, DC. R.F. Lim (Ed.).
15. Tseng W.-S. Culture, ethnicity, and drug therapy. Handbook of cultural psychiatry 2001, 505-511. Academic Press, San Diego (CA).
16. Tseng W.-S. Ethnicity, culture, and drug therapy. Clinician's guide to cultural psychiatry 2003, 343-352. Academic Press, Boston.
17. Ng CH, Lin K-M, Singh BS, et al. Review of ethno-psychopharmacology: advances in current practice 2008, Cambridge University Press, New York, p. 38-62.
18. Miskimen T., Marin H., Escobar J. Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology (Berl) 2003, 171:98-104.
19. Lawson W.B. Biological markers in neuropsychiatric disorders: racial and ethnic factors. Family, culture, and psychobiology 1990, Levas, New York. E. Sorel (Ed.).
20. Vitiello B. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology (Berl) 2007, 191(1):5-13.
21. Olfson M., Marcus S.C., Weissman M.M., et al. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002, 41:514-521.
22. Timimi S., Taylor E. ADHD is best understood as a cultural construct. Br J Psychiatry 2004, 184:8-9.
23. Kleinman A. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med 1978, 88:251-258.
24. Harwood A. The hot-cold theory of disease: implications for treatment of Puerto Rican patients. JAMA 1971, 216:1153-1160.
25. Winters N.C., Hanson G., Stoyanova V. The case formulation in child and adolescent psychiatry. Child Adolesc Psychiatr Clin N Am 2007, 16:111-132.
26. Engel G.L. From biomedical to biopsychosocial: being scientific in the human domain. Psychosomatics 1997, 38(6):521-528.
27. Barker P. The child and adolescent psychiatry evaluation: basic child psychiatry 1995, Blackwell Scientific, Oxford (UK).
28. Nurcombe B., Drell M., Leonard H., et al. Clinical problem solving: the case of Matthew, part 1. J Am Acad Child Adolesc Psychiatry 2002, 41(1):92-97.
29. Nurcombe B. Developmental psychopathology and the diagnostic formulation. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, October 1992.
30. Lin K.-M., Smith M.W., Ortiz V. Culture and psychopharmacology. Psychiatr Clin N Am 2001, 24(3):523-538.
31. Lawson W.B. Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacol Bull 1986, 32:275-281.
32. Pi E.H., Simpson G.M. Cross-cultural psychopharmacology: a current clinical perspective. Psychiatr Serv 2005, 56:31-33.
33. Lin K.-M., Finder E. Neuroleptic dosage for Asians. Amer Jnl of Psychiatry 1983, 140:490-491.
34. Lawson W.B. Racial and ethnic factors in psychiatric research. Hosp Community Psychiatry 1986, 37:50-54.
35. Lawson W.B., Yesavage J.A., Werner R.D. Race, violence, and psychopathology. J Clin Psychiatry 1984, 45:294-297.
36. Segal S.P., Bola J.R., Watson M.A. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996, 47:282-286.
37. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993, 50:723-733.
38. Jeste D.V., Caligiuri M.P., Paulsen J.S. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995, 52:756-765.
39. Glazer W.M., Morgenstern H., Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994, 45:38-42.
40. Lindamer L., Lacro J.P., Jeste D.V. Relationship of ethnicity to the effects of antipsychotic medication. Cross cultural psychiatry 1999, John Wiley & Sons, Chichester (West Sussex). J.M. Herrara, W.B. Lawson, J.J. Sramek (Eds.).
41. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
42. Lin K.M. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001, 62(Suppl 13):13-19.
43. Chillevoort I., de Boer A., van der Weide J., et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 2002, 12:235-240.
44. de Leon J., Susce M.T., Pan R.M., et al. CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005, 66:15-27.
45. Lawson W.B. " Issues in the pharmacotherapy of African Americans" Review of psychiatry, vol. 19, no. 4 2000, 37-53. American Association Press, Washington, DC. P. Ruiz (Ed.).
46. Tollefson G.D., Beasley C.M., Tran V.P., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154:457-465.
47. Tran P.T., Lawson W.B., Andersen S., et al. Treatment of the African American patient with novel antipsychotic agents. Cross cultural psychiatry 1999, John Wiley & Sons, Chichester (UK). J. Herrera, W.B. Lawson, J. Sramek (Eds.).
48. Bailey R.K. Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. J Natl Med Assoc 2003, 95(2):137-144.
49. Fenton W.S., Chavez M.R. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 2006, 163:1697-1704.
50. Okpaku S., Frazer A., Mendels J. A pilot study of racial differences in erythrocyte lithium transport. Am J Psychiatry 1980, 137:120-121.
51. Strickland T.L., Lin K.-M., Fu P., et al. Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biol Psychiatry 1995, 37:325-330.
52. Strickland T.L., Lawson W.B., Lin K-M. Interethnic variation in response to lithium therapy among African-American and Asian-American populations. Psychopharmacology and psychobiology of ethnicity 1993, 107-123. American Psychiatric Association, Washington, DC. K.-M. Lin, R.E. Poland, G. Nakasaki (Eds.).
53. Hildreth C., Saunders O. Hypertension in blacks: clinical overview. Cardiovasc Clin 1991, 21:85-96.
54. Valenstein M., McCarthy J.F., Austin K.L., et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006, 163:1219-1225.
55. Kilbourne A.M., Pincus H.A. Patterns of psychotropic medication use by race among veterans with bipolar disorder. Psychiatr Serv 2006, 57:123-126.
56. McMahon F.J., Buervenich S., Charney D., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78:804-814.
57. Melfi C.A., Croghan T.W., Hanna M.P., et al. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry 2000, 61:16-21.
58. Kuruppurachchi K., Wijeratne L. ADHD in developing countries. Br J Psychiatry 2004, 185(5):439.
59. Samuel V., Curtis S., Thornell A., et al. The unexplored void of ADHD and African-American research: a review of the literature. J Atten Disord 1997, 1(4):197-207.
60. Miller T., Nigg J., Miller R. Attention deficit hyperactivity disorder in African American children: what can be concluded from the past ten years?. Clin Psychol Rev 2009, 29(1):77-86.
61. Winsberg B.G., Comings D.E. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999, 38:1474-1477.
62. Waldman I.D., Rowe D.C., Abramowitz A., et al. Association and linkage of the dopamine transporter gene and attention-deficit/hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998, 63:1767-1776.
63. Arnold L., Elliott M., Sachs L., et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol 2003, 71(4):713-727.
64. Brown R.T., Sexson S.B. A controlled trial of methylphenidate in black adolescents. Attentional, behavioral and physiological effects. Clin Pediatr 1988, 27:74-81.
65. Starr H., Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc 2005, 97(Suppl 10):S11-S16.
66. Corbie-Smith G., Thomas S.B., Williams M.V., et al. Attitudes and beliefs of African-American toward participation in medical research. J Gen Intern Med 1999, 14:537-546.
67. Shavers V.L., Lynch C.F., Burmeister L.F. Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies. J Natl Med Assoc 2000, 92:563-572.
68. Shavers V.L., Lynch C.F., Burmeister L.F. Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol 2002, 12:248-256.
69. Hamilton L.A., Aliyu M.H., Lyons P.D., et al. African-American community attitudes and perceptions toward schizophrenia and medical research: an exploratory study. J Natl Med Assoc 2006, 98:18-27.
70. Wendler D., Kington R., Madans J., et al. Are racial and ethnic minorities less willing to participate in health research?. PLoS Med 2006, 3:e19.
71. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
72. Stroup T.S., Lieberman J.A., McEvoy J.P., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163:611-622.
73. Metzl J.A. Forming an effective therapeutic alliance. The doctor-patient relationship in pharmacotherapy: improving treatment effectiveness 2000, 25-47. Guilford Press, New York. A. Tasman, M.B. Riba, K.R. Silk (Eds.).
74. Broucek F., Ricci W. Self-disclosure of self-presence?. Bull Menninger Clin 1998, 26(4):427-438.
75. Havens L. Forming effective relationships. The real world guide to psychotherapy practice 2000, 17-33. Harvard University Press, Cambridge (MA). L. Havens, A. Sabo (Eds.).
76. Joshi S.V. Teamwork: the therapeutic alliance in pediatric pharmacotherapy. Child Adolesc Psychiatr Clin N Am 2006, 15:239-262.
77. Sabo A., Rand B. The relational aspects of psychopharmacology. The real world guide to psychotherapy practice 2000, 34-59. Harvard University Press, Cambridge (MA). A. Sabo, L. Havens (Eds.).
78. O'Brien J.D., Perlmutter I. The effect of medication on the process of psychotherapy. Child Adolesc Psychiatr Clin N Am 1997, 6(1):185-196.
79. Feinstein N.R., Fielding K., Udvari-Solner A., et al. The supporting alliance in child and adolescent treatment: enhancing collaboration among therapists, parents, and teachers. Am J Psychother 2009, 63(4):319-344.
80. Kemper K.J., Vohra S., Walls R., et al. The use of complementary and alternative medicine in pediatrics. Pediatrics 2008, 122:1374-1386.
81. Graham R.E., Ahn A.C., Davis R.B., et al. Use of complementary and alternative medical therapies among racial and ethnic minority adults: results from the 2002 National Health Interview Survey. J Natl Med Assoc 2005, 97(4):535-545.
82. Guenther E., Mendoza J., Crouch B.I., et al. Differences in herbal and dietary supplement use in Hispanic and non-Hispanic pediatric populations. Pediatr Emerg Care 2005, 21(8):507-514.
83. Smitherman L.C., Janisse J., Mathur A. The use of folk remedies among children in an urban black community: remedies for fever, colic, and teething. Pediatrics 2005, 115(3). Available at:, Accessed August 11, 2010. http://www.pediatrics.org/cgi/content/full/115/3/e297.
84. Novins D.K., Beals J., Moore L.A., et al. Use of biomedical services and traditional healing options among American Indians: sociodemographic correlates, spirituality, and ethnic identity. Med Care 2004, 42(7):670-679.
85. Van Sickle D., Morgan F., Wright A.L. Qualitative study of the use of traditional healing by asthmatic Navajo families. Am Indian Alsk Native Ment Health Res 2003, 11(1):1-18.
86. Anderson S.L., Navalta C.P. Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci 2004, 22(5-6):423-440.
87. Chan E., Rappaport L.A., Kemper K.J. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr 2003, 24(1):4-8.
88. Wender E.H. The food additive-free diet in the treatment of behavior disorders: a review. J Dev Behav Pediatr 1986, 7(1):35-42.
89. Rojas N.L., Chan E. Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Ment Retard Dev Disabil Res Rev 2005, 11(2):116-130.
90. Diet and attention deficit hyperactivity disorder The Harvard mental health letter. [1057-5022] 2009, 25(12):4-5.
91. Weber W., Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 2007, 54(6):983-1006.
92. Cormier E., Elder J.H. Diet and child behavior problems: fact or fiction?. Pediatr Nurs 2007, 33(2):138-143.
93. Voigt R.G., Llorente A.M., Jensen C.L., et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001, 139(2):189-196.
94. Stevens L.J., Zentall S.S., Deck J.L., et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995, 62(4):761-768.
95. Sinn N., Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007, 28(2):82-91.
96. Mitchell E.A., Aman M.G., Turbott S.H., et al. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 1987, 26(8):406-411.
97. Bekaroglu M., Aslan Y., Gedik Y., et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 1996, 37:225-227.
98. Stevens L.J., Zentall S.S., Abate M.L., et al. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav 1996, 59:915-920.
99. Richardson A.J., Puri B.K. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26(2):233-239.
100. Stevens L., Zhang W., Peck L., et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003, 38(10):1007-1021.
101. Sorgi P.J., Hallowell E.M., Hutchins H.L., et al. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J 2007, 6:16.
102. Yorbik O., Ozdag M.F., Olgun A., et al. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(3):662-667.
103. Arnold L.E., DiSilvestro R.A. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005, 15(4):619-627.
104. Oner O., Alkar O.Y., Oner P. Relation of ferritin levels with symptom ratings and cognitive performance in children with attention deficit-hyperactivity disorder. Pediatr Int 2008, 50(1):40-44.
105. Konofal E., Lecendreux M., Deron J., et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008, 38(1):20-26.
106. Van Oudheusden L.J., Scholte H.R. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2002, 67(1):33-38.
107. Lyon R., Cline J.C., Totosy de Zepetnek J., et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci 2001, 26(3):221-228.
108. Trebaticka J., Kopasova S., Hradecna Z., et al. Treatment of ADHD with French maritime pine bark extract, pycnogenol. Eur Child Adolesc Psychiatry 2006, 15(6):329-335.
109. Nathan P.J., Tanner S., Lloyd J., et al. Effects of a combined extract of Ginkgo biloba and Bacopa monnieri on cognitive function in healthy humans. Hum Psychopharmacol 2004, 19(2):91-96.
110. Lan Y., Zhang L.-L., Luo R. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate. J Int Med Res 2009, 37(3):939-948.
111. Jensen P.S., Kenny D.T. The effects of yoga on the attention and behavior of boys with attention-deficit/hyperactivity disorder (ADHD). J Atten Disord 2004, 7(4):205-216.
112. Khilnani S., Field T., Hernandez-Reif M., et al. Massage therapy improves mood and behavior of students with attention-deficit/hyperactivity disorder. Adolescence 2003, 38(152):623-638.
113. Butnik S.M. Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder. J Clin Psychol 2005, 61(5):621-625.
114. Monastra V.J. Quantitative electroencephalography and attention-deficit/hyperactivity disorder: implications for clinical practice. Curr Psychiatry Rep 2008, 10(5):432-438.
115. Gevensleben H., Holl B., Albrecht B., et al. Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. J Child Psychol Psychiatry 2009, 50(7):780-789.
116. Kandel E. Psychotherapy and the single synapse: the impact of psychiatric thought on neurobiologic research. N Engl J Med 1979, 301(19):1028-1037.